Previous Article
Liminal BioSciences Announces First Subject Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras
Liminal BioSciences Announces First Subject Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras

LMNL today announced that the first subject has been dosed in the Company’s fezagepras Phase 1 multiple asc...

Next Flipbook
Quarterly Report Q2 2020
Quarterly Report Q2 2020

Go to Liminal BioSciences Q3 Results Conference Call on Friday, Nov 13, 2020 8:30 AM EST

View Now